Loading
FX-909 is an experimental pill from Flare Therapeutics, in phase 1 trials for advanced urothelial (bladder) cancer.
FX-909 is a small molecule, oral from Flare Therapeutics. Blocks PPARG, a transcription factor that the company describes as the master regulator of the luminal lineage of bladder cancer cells. The phase 1 study NCT05929235 tests it alone and with pembrolizumab; the company describes a randomised phase 1b part in PPARG-high locally advanced or metastatic urothelial cancer after earlier treatment. Whether it works in people has not been established.
Blocks PPARG, a transcription factor that the company describes as the master regulator of the luminal lineage of bladder cancer cells. Connects to PPARG.
1.FX-909 slips into a pocket on PPARG.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"FX-909" OR ABSTRACT:"FX-909") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FX-909, not a curated reading list.
Shares Flare Therapeutics and the tag pipeline.
Shares Flare Therapeutics and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/